Company Overview and News

to your dashboard

Headline News

How Did Jazz Pharmaceuticals Perform in 3Q17?

In 3Q17, Jazz Pharmaceuticals (JAZZ) generated revenue of $411.9 million, which reflected a ~10% rise on a year-over-year (or YoY) basis and a 4% rise on a quarter-over-quarter basis. (31-0)

A Look at Edwards Lifesciences’ 2018 Sales Guidance

Edwards Lifesciences (EW) expects to generate sales growth of 9%–10% in 2018. This underlying sales growth range is narrower than the company’s dollar sales guidance of $3.5 billion–$3.9 billion. Foreign exchange is expected to have a minimal impact of 0.5% on the company’s total sales in 2018. Peers Boston Scientific (BSX), Abbott Laboratories (ABT), and Baxter International (BAX) expect to generate sales growth of approximately 6. (101-1)

Edwards Lifesciences Expands Portfolio with Harpoon Medical Acquisition

2018-01-01 marketrealist
On December 6, 2017, Edwards Lifesciences (EW) announced the completion of its acquisition of Harpoon Medical for $100 million in cash on December 1, 2017. Up to $150 million of milestone-based payments are expected to be paid over the next ten years. The acquired business will be added to Edwards Lifesciences’ Surgical Heart Valve Therapy portfolio. (35-0)

Discussing Analysts’ Latest Recommendations on VAR Stock

2017-12-27 marketrealist
Varian Medical Systems (VAR) is a better-aligned, leaner business with a strong market position after the spin-off of Varex Imaging (VREX) in January 2017. The company is now focused on its core capability: accelerating its position in the cancer-management market. For a discussion on the company’s future potential, read How Is Varian Positioned for 2018 after 2017 Transformation? (38-0)

What Can We Expect from Wyndham in 2Q17?

2017-07-25 marketrealist
Analysts expect Wyndham Worldwide’s (WYN) revenue to rise 4.7% year-over-year (or YoY) to $1.5 billion and its earnings before interest, tax, depreciation, and amortization (or EBITDA) to rise 2.4% to $349.3 million in 2Q17.

Edwards Lifesciences Gets ‘Buy’ Ratings from 77% of Analysts

2017-06-26 marketrealist
Edwards Lifesciences (EW) is one of the leading players in the artificial valve market. EW stock witnessed a declining trend toward the end of 2016 after the company posted disappointing 2Q16 results. However, it has been recovering recently and returned ~26.5% YTD (year-to-date).

Best And Worst Q2 2017: Mid Cap Growth ETFs And Mutual Funds

2017-06-05 seekingalpha
BFOR is our top-rated Mid Cap Growth ETF and ERSMX is our top-rated Mid Cap Growth mutual fund.

The Zacks Analyst Blog Highlights: iShares Core S&P Mid-Cap ETF, iShares Russell Mid-Cap ETF, Vanguard Mid-Cap Growth ETF, iShares S&P Mid-Cap 400 Growth ETF and Schwab U.S. Mid-Cap ETF

2017-04-21 zacks
Chicago, IL – April 21, 2017 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include iShares Core S&P Mid-Cap ETF (NYSEARCA: (IJH - Free Report) – Free Report ), iShares Russell Mid-Cap ETF (NYSEARCA: (IWR - Free Report) – Free Report ), Vanguard Mid-Cap Growth ETF (NYSEARCA: (VOT - Free Report) – Free Report ), iShares S&P Mid-Cap 400 Growth ETF (NYSEARCA: (IJK - Free Report) – Free Report ) and Schwab U.

Buy-Ranked Mid-Cap ETFs for a Shaky Market

2017-04-20 zacks
The first quarter was great for the U.S. stock market with the major benchmarks logging in the best quarterly performance in many years. However, the bullish trend seems to be stalling with the rise in volatility and uncertainty as well as fading of Trump trade. This is especially true against the backdrop of feeble data and growing geopolitical tensions. In particular, the latest round of economic data disappointed for the first time since the U.

5 Unbeatable ETF Strategies for Q2

2017-04-06 zacks
The first quarter of 2017 was great for the financial world thanks to easing policies and improving health of the economy amid bouts of volatility. This is especially true as the MSCI All-Country World Index logged in the best quarterly gain of more than 6% representing the best start to the year since 2012. Moreover, the S&P 500 notched its best three-month stretch since the fourth quarter of 2015.

Baron: Under Armour Is Cheap Compared to the Last Couple of Years

2017-02-21 marketrealist
Under Armour (UA) is currently struggling to meet investors’ expectations, as it missed analysts’ estimates in 4Q16. The company reported a 12% rise in revenue in the quarter, missing expectations by $100 million. Some of the ETFs holding Under Armour include the Vanguard Mid-Cap Growth ETF (VOT) and the Consumer Discretionary Select Sector SPDR ETF (XLY).

What Can We Expect from Wyndham in 4Q16?

2017-02-10 marketrealist
Wyndham (WYN) is expected to report its 4Q16 earnings on February 15, 2017, before the market opens for the day. Analysts are estimating 4Q16 revenues to rise 1.4% to $1.3 billion and earnings per share to rise 32% to $1.30.

5 Growth ETFs & Stocks Set for Explosive Gains in 2017

2017-01-11 zacks
The 2016 solid performance of the U.S. stocks has continued into 2017, that too with huge optimism. While the rally has been broad-based, growth stocks are easily leading the way to start the year. This is especially true as the ultra-popular growth fund (QQQ - Free Report) climbed 3.5% in the first few trading sessions compared with gains of 0.4% for the value fund IWD and 1.3% for the core fund (SPY - Free Report) .

Piper Jaffray Downgrades Michael Kors Holdings to ‘Neutral’

2017-01-05 marketrealist
Michael Kors Holdings (KORS) has a market cap of $7.1 billion. It rose 0.23% to close at $43.08 per share on January 3, 2017. The stock’s weekly, monthly, and year-to-date (or YTD) price movements were 0.56%, -6.8%, and 0.23%, respectively, on the same day.

3 Mid Cap Growth ETFs To Buy For Q4

2015-09-25 seekingalpha
Increasing uncertainty pertaining to the China turmoil, global growth worries, slumping commodities and timing of the interest rates hike in the U.S. are general concerns. In this backdrop that has la

CUSIP: 922908538